Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490811 | 0.96 | MTNR1B (0.65) | MTNR1BMTNR1AL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL13411722 | 0.79 | MTNR1A (0.70) | MTNR1BMTNR1AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13490816 | 0.78 | FFAR1 (0.54) | CNR1CNR2 | |
| SCHEMBL13490817 | 0.77 | CNR1 (0.51) | ALDH1A1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL18183526 | 0.77 | SMN1; SMN2 (0.70) | MTNR1BMTNR1ACNR1CNR2SMN1; SMN2 | |
| SCHEMBL88959 | 0.75 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL13490807 | 0.75 | CNR1 (0.44) | ALDH1A1CNR1CNR2RECQL | |
| SCHEMBL88961 | 0.75 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2 | |
| SCHEMBL13490815 | 0.74 | BRD4 (0.47) | L3MBTL1ALDH1A1CNR1CNR2SMN1; SMN2 | |
| SCHEMBL1911330 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | MTNR1B 738/4885MTNR1A 1360/4885L3MBTL1 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.